Correlation versus causation? pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous adr reporting

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Anderson, Nora ^a   Borlak, Juergen ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTINUCLEAR ANTIBODY; CELECOXIB; CITRATE POTASSIUM; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRONE; DOXEPIN; ENOXAPARIN; ESTRADIOL; ETORICOXIB; FLUINDOSTATIN; FLUPIRTINE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INSULIN; LEVOTHYROXINE; LUMIRACOXIB; MITOCHONDRION ANTIBODY; NON PRESCRIPTION DRUG; NORETHISTERONE; PREGABALIN; PROMETHAZINE; ROFECOXIB; TRAMADOL; ZOLPIDEM;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GUILLAIN BARRE SYNDROME; HEALTH CARE PERSONNEL; HEPATOBILIARY DISEASE; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RATING SCALE; RISK BENEFIT ANALYSIS; SCORING SYSTEM; UNITED STATES;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AMINOPYRIDINES; ANALGESICS; BILE DUCT DISEASES; CAUSALITY; DRUG-INDUCED LIVER INJURY; FEMALE; GERMANY; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHARMACOVIGILANCE; VIRUS DISEASES; WORLD HEALTH ORGANIZATION;

EID: 80054122083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025221     Document Type: Article

References (44)

1. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, et al. (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274: 29-34.
2. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, et al. (1997) The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 277: 307-311.
3. Bero LA, Lipton HL, Bird JA, (1991) Characterization of geriatric drug-related hospital readmissions. Med Care 29: 989-1003.
4. Dartnell JG, Anderson RP, Chohan V, Galbraith KJ, Lyon ME, et al. (1996) Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 164: 659-662.
5. Mokdad AH, Marks JS, Stroup DF, Gerberding JL, (2004) Actual causes of death in the United States, 2000. JAMA 291: 1238-1245.
6. Wysowski DK, Swartz L, (2005) Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 165: 1363-1369.
7. Lee WM, (2003) Drug-induced hepatotoxicity. N Engl J Med 349: 474-485.
8. Stricker BH, Psaty BM, (2004) Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-47.
9. Harpe SE, (2009) Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy 29: 138-153.
10. Brown DA, Passmore GM, (2009) Neural KCNQ (Kv7) channels. Br J Pharmacol 156: 1185-1195.
11. Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG, (1999) Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm 106: 857-867.
12. Schwabe U, Paffrath D, (2008) Arzneiverordnungs-Report 2007 Heidelberg, Germany Springer Medizin Verlag.
13. Arzneimittelkommission der deutschen Ärzteschaft (2007) Leberschäden unter Flupirtin (Aus der UAW-Datenbank). Dtsch Arztebl 104 (46): A 3200.
14. Shakir SA, Layton D, (2002) Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 25: 467-471.
15. Hill AB, (1965) The Environment and Disease: Association or Causation? Proc R Soc Med 58: 295-300.
16. Teschke R, Schwarzenboeck A, Hennermann KH, (2008) Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 66: 758-766.
17. Hennekens CH, Buring JE, (1987) Screening. In: Mayrent SL, editors. Epidemiology in Medicine Boston Little, Brown and Company pp. 327-347.
18. Danan G, Benichou C, (1993) Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46: 1323-1330.
19. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR, (1997) Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 17: 374-389.
20. Welsch M, Alt M, Richard MH, Imbs JL, (2000) The French pharmacovigilance system: structure and missions. Presse Med 29: 102-106.
21. Rajab M, Lagier G, Eftekhari P, Ginisty S, Bazire A, et al. (2004) Child overdose: the value of the French pharmacovigilance causality assessment method. Therapie 59: 603-606.
22. Garcia-Cortes M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, et al. (2008) Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 27: 780-789.
23. Naprienko MV, Filatova EG, (2006) Use of katadolon in the treatment of abuse headache. Zh Nevrol Psikhiatr Im S S Korsakova 106: 38-41.
24. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, et al. (2009) How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 104: 356-362.
25. Aithal GP, Day CP, (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11: 563-vii.
26. Herrmann WM, Kern U, Aigner M, (1987) On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 63 (Suppl 3): 87-103.
27. Clinard F, Sgro C, Bardou M, Hillon P, Dumas M, et al. (2004) Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol 60: 279-283.
28. Bate A, Lindquist M, Edwards IR, (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22: 127-140.
29. Ringe JD, Miethe D, Pittrow D, Wegscheider K, (2003) Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain. A multivariate analysis. Arzneimittelforschung 53: 496-502.
30. Goodchild CS, Nelson J, Cooke I, Ashby M, Jackson K, (2008) Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer. Pain Med 9: 939-949.
31. Kamchatnov PR, Btysheva TT, Ganzhula PA, Gaponova OV, Zhuravleva EIu, et al. (2006) [The use of katadolon in patients with spondylogenic dorsalgia]. Zh Nevrol Psikhiatr Im S S Korsakova 106: 46-48.
32. Li C, Ni J, Wang Z, Li M, Gasparic M, et al. (2008) Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial*. Curr Med Res Opin 24: 3523-3530.
33. Muller-Schwefe GH, Uberall MA, (2008) Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW Fortschr Med 149 (Suppl 4): 153-161.
34. Pothmann R, Lobisch M, (2000) [Acute treatment of episodic childhood tension-type headache with flupirtine and paracetamol - a double-blind crossover-study]. Schmerz 14: 1-4.
35. Powell-Jackson P, Williams R, (1985) Use of flupirtine maleate as an analgesic in patients with liver disease. Br J Clin Pract 39: 63-66.
36. Methling K, Reszka P, Lalk M, Vrana O, Scheuch E, et al. (2009) Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metab Dispos 37: 479-493.
37. Hlavica P, Niebch G, (1985) [Pharmacokinetics and biotransformation of the analgesic flupirtine in humans]. Arzneimittelforschung 35: 67-74.
38. Niebch G, Borbe HO, Hummel T, Kobal G, (1992) Dose-proportional plasma levels of the analgesic flupirtine maleate in man. Application of a new HPLC assay. Arzneimittelforschung 42: 1343-1345.
39. Schluter T, Struy H, Schonfeld P, (2000) Protection of mitochondrial integrity from oxidative stress by the triaminopyridine derivative flupirtine. FEBS Lett 481: 42-46.
40. Dhar S, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, et al. (2002) Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic. Ann Neurol 51: 448-466.
41. Perovic S, Schleger C, Pergande G, Iskric S, Ushijima H, et al. (1994) The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur J Pharmacol 288: 27-33.
42. Boscia F, Annunziato L, Taglialatela M, (2006) Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 51: 283-294.
43. Gassen M, Lamensdorf I, Armony T, Finberg JP, Youdim MB, (2003) Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J Neural Transm 110: 171-182.
44. Schroder HC, Muller WE, (2002) Neuroprotective effect of flupirtine in prion disease. Drugs Today (Barc) 38: 49-58.